Prediabetes; why and how would we look for it? | Professor Anette-Gabriele Ziegler скачать в хорошем качестве

Prediabetes; why and how would we look for it? | Professor Anette-Gabriele Ziegler

This keynote was filmed at Metabolism Day on March 14, 2023 at the University of Copenhagen. Metabolism Day is a conference about energy control and metabolism, and is hosted by the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR). For more information please visit: http://cbmr.ku.dk A specialist in internal medicine, endocrinology, and diabetes, Professor Dr. Anette-Gabriele Ziegler leads the Institute of Diabetes Research at Helmholtz Munich, and is Chair of Diabetes at the Faculty of Medicine, Technical University Munich, Germany. She is also speaker of the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD), and an academy head of the German Center for Diabetes Research DZD e.V. Dr. Ziegler's primary research goal is understanding the pathogenesis of type 1 diabetes and finding a preventive treatment for a world without type 1 diabetes. Her main research focuses on identification of genetic, immune and environmental determinants of the disease, the introduction of polygenic risk scores, and the translation of findings into predictive staging that enables trials to prevent type 1 diabetes. She initiated the landmark and worldwide first birth cohort study in diabetes, BABYDIAB, with seminal discoveries on the precocious start of islet autoimmunity in the first year of life, and insulin as the initial target of autoantibodies. The success of the BABYDIAB study led to the multinational birth-cohort initiative TEDDY (The Environmental Determinant of Diabetes in the Young), of which she is Principal Investigator for the German Clinical Center. She cofounded GPPAD, which introduced polygenic risk score-based newborn screening and also started the first population-based screening for early stage type 1 diabetes in childhood, the Fr1da-study, which has paved the way for prevention trials in a public health setting. She is a member of the TRIALNET, TEDDY, INNODIA, and GPPAD consortia.